Nuvectis Pharma Inc美股招股说明书(2026-06-29版)

SUBJECT TO COMPLETION, DATED JUNE 29, 2026 PRELIMINARY PROSPECTUS SUPPLEMENT(to Prospectus dated February20, 2026) We are offeringshares of our common stock, par value $0.00001 per share, in this offering. Our common stock is listed on The Nasdaq Capital Market under the symbol “NVCT”. On June26, 2026 the last reportedsale price of our common stock on The Nasdaq Capital Market was $27.19 per share. We are an “emerging growth company” as defined in Section2(a)of the Securities Act of 1933, as amended (the “SecuritiesAct”) and a “smaller reporting company” as defined under Rule405 of the Securities Act and, as such, we have elected to comply withcertain reduced public company reporting requirements. See “Prospectus Summary—Emerging Growth Company and SmallerReporting Company.” Investing in our common stock involves a high degree of risk. See “Risk Factors” beginning on pageS-6 of thisprospectussupplement and in the documents incorporated by reference into this prospectus supplement and theaccompanying prospectus. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved ofthese securities or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Anyrepresentation to the contrary is a criminal offense. Public offering priceUnderwriting discounts and commissions We have granted the underwriters an option for a period of 30 days to purchase an additionalshares of our commonstock, at the public offering price, less the underwriting discount. If the underwriters exercise the option in full, the total underwritingdiscounts and commissions payable by us will be $, and the total proceeds to us, before expenses will be $. Delivery of the shares of common stock is expected to be made on or about, 2026. Sole Bookrunner Cantor Prospectus Supplement dated, 2026 TABLE OF CONTENTS PageProspectus supplementAbout this prospectus supplementS-1Prospectus supplement summaryS-2Risk factorsS-6Special cautionary notice regarding forward-looking statementsS-14Use of proceedsS-15Dividend policyS-16CapitalizationS-17DilutionS-18UnderwritingS-19Legal mattersS-26ExpertsS-27Where you can find more informationS-28Incorporation of certain information by referenceS-29 PageProspectusAbout This ProspectusiNuvectis Pharma,Inc.1The Offering2Risk Factors2Forward-Looking Statements2Where You Can Find More Information3Incorporation of Certain Information by Reference3Description of Securities We MayOffer3Description of Warrants6Description of Debt Securities7Description of Units10Plan of Distribution10Legal Matters12Experts12 We have not authorized any other person to provide any information other than that contained or incorporated byreference into this prospectus supplement, the accompanying prospectus or in any free writing prospectus prepared by or onbehalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliabilityof, any other information that others may give you. You should not assume that the information contained in this prospectussupplement or the accompanying prospectus is accurate as of any date other than the date of this prospectus supplement or theaccompanying prospectus, or that information contained in any document incorporated or deemed to be incorporated byreference is accurate as of any date other than the date of that document. Our business, financial condition, results ofoperations and prospects may have changed since that date. You should read this prospectus supplement, the accompanyingprospectus, the documents incorporated by reference in this prospectus supplement and the accompanying prospectus, andany free writing prospectus that we have authorized for use in connection with this offering, in their entirety before making aninvestment decision. You should also read and consider the information in the documents to which we have referred you in thesections of this prospectus supplement entitled “Where You Can Find More Information” and “Incorporation of CertainInformation by Reference.” ABOUT THIS PROSPECTUS SUPPLEMENT This document is in two parts. The first part is this prospectus supplement, which describes the specific terms of this offeringof common stock and also adds to and updates information contained in the accompanying prospectus and the documents incorporatedby reference in this prospectus supplement and the accompanying prospectus. The second part, the accompanying prospectus, datedFebruary20, 2026, provides more general information, some of which may not apply to this offering. Generally, when we refer to thisprospectus supplement, we are referring to both parts of this document combined. To the extent there is a conflict between theinformation contained in this prospectus supplement and the information contained in the accompanying prospectus or any documentincorporated by reference that was filed with the U.S. Securities and Exchange